Technical Analysis for KPTI - Karyopharm Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical KPTI trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Crossed Above 20 DMA | Bullish | -9.51% | |
| Bollinger Band Squeeze | Range Contraction | -9.51% | |
| Up 3 Days in a Row | Strength | -9.51% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/26/2020
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate includes Selinexor, an oral selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, a SINE compound that is in Phase IIb clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.
Medicine Cancer Pharmaceutical Diseases Treatment Of Cancer Oncology Chemotherapy Occupational Safety And Health Antibody Drug Conjugates Pixantrone
Medicine Cancer Pharmaceutical Diseases Treatment Of Cancer Oncology Chemotherapy Occupational Safety And Health Antibody Drug Conjugates Pixantrone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.09 |
| 52 Week Low | 3.92 |
| Average Volume | 1,207,334 |
| 200-Day Moving Average | 10.22 |
| 50-Day Moving Average | 17.21 |
| 20-Day Moving Average | 18.61 |
| 10-Day Moving Average | 18.25 |
| Average True Range | 1.04 |
| ADX | 23.73 |
| +DI | 22.91 |
| -DI | 28.37 |
| Chandelier Exit (Long, 3 ATRs ) | 16.96 |
| Chandelier Exit (Short, 3 ATRs ) | 19.83 |
| Upper Bollinger Band | 19.94 |
| Lower Bollinger Band | 17.27 |
| Percent B (%b) | -0.09 |
| BandWidth | 14.35 |
| MACD Line | 0.25 |
| MACD Signal Line | 0.49 |
| MACD Histogram | -0.2467 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.91 | ||||
| Resistance 3 (R3) | 20.20 | 19.55 | 19.43 | ||
| Resistance 2 (R2) | 19.55 | 18.82 | 19.40 | 19.27 | |
| Resistance 1 (R1) | 18.29 | 18.37 | 17.97 | 18.00 | 19.11 |
| Pivot Point | 17.64 | 17.64 | 17.47 | 17.49 | 17.64 |
| Support 1 (S1) | 16.38 | 16.91 | 16.06 | 16.09 | 14.97 |
| Support 2 (S2) | 15.73 | 16.46 | 15.58 | 14.81 | |
| Support 3 (S3) | 14.47 | 15.73 | 14.65 | ||
| Support 4 (S4) | 14.18 |
